[当前在心力衰竭治疗中使用葡萄糖辅运输体2抑制剂]
Yüksel Çavuşoğlu1, Hakan Altay2, Ahmet Çelik3
1Department of Cardiology, Eskisehir Osmangazi University Faculty of Medicine, Eskisehir, Türkiye.
概括
-葡萄糖共传输体-2 抑制剂 (SGLT2i) 对心力衰竭 (HF) 患者提供了显著的益处,减少住院治疗和改善生活质量. 这些发现导致了对HF的更新治疗指南,包括减少射出分数 (HFrEF) 的HF和保存射出分数 (HFpEF) 的HF.
科学领域:
- 心脏病学 心脏病学
- 腎臟病學 (nephrology) 是一種醫學.
- 药理学 药理学是指药理学的学科.
背景情况:
- -葡萄糖共传输体-2 抑制剂 (SGLT2i) 已知在2型糖尿病 (T2DM) 中降低葡萄糖的作用.
- 之前的研究表明,SGLT2i可减少心血管疾病或患有心血管疾病或风险因素的T2DM患者的心血管事件和心力衰竭 (HF) 住院治疗.
- 在HF住院的显著减少表明HF患者的潜在好处.
研究的目的:
- 提供SGLT2抑制剂在治疗心力衰竭中的作用的全面概述.
- 综合最近关于不同高频群体SGLT2i疗效的证据.
主要方法:
- 对临床试验数据的审查,包括DAPA-HF, EMPEROR-减少, EMPEROR-保存, DELIVER, EMPULSE,以及DICTATE-AHF.
- 分析SGLT2i对心血管死亡率,HF住院和HFrEF,HFpEF和急性HF患者的生活质量的影响.
主要成果:
- SGLT2抑制剂在HFrEF患者中显示出明显的临床益处,减少HF住院和改善生活质量.
- 最近的试验证实了SGLT2i在HFpEF患者 (EMPEROR-Preserved, DELIVER) 的疗效.
- 证据也支持SGLT2i在住院急性HF患者 (EMPULSE,DICTATE-AHF) 的使用.
结论:
- 现在,SGLT2抑制剂是心力衰竭的基石疗法,对HFrEF和HFpEF的治疗指南产生影响.
- 证据支持扩大SGLT2抑制剂的使用范围,超越糖尿病管理,进入HF治疗.
- SGLT2 抑制剂在治疗各种形式的心力衰竭方面取得了重大进展.
相关概念视频
01:26Heart Failure Drugs: Inotropic Agents
545
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
545
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
404
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
404
01:55Secondary Active Transport
118.5K
One example of how cells use the energy contained in electrochemical gradients is demonstrated by glucose transport into cells. The ion vital to this process is sodium (Na+), which is typically present in higher concentrations extracellularly than in the cytosol. Such a concentration difference is due, in part, to the action of an enzyme “pump” embedded in the cellular membrane that actively expels Na+ from a cell. Importantly, as this pump contributes to the high concentration of...
118.5K
01:22Heart Failure Drugs: Diuretics
352
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
352
01:22Heart Failure Drugs: β-Blockers
322
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
322
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
183
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
183